Evaluation of DUPAN-2 in Pancreatic Cancer
Author Information
Author(s): E.H. Cooper, M.A. Forbes, M. Taylor
Primary Institution: The University of Leeds
Hypothesis
Can DUPAN-2 levels in serum effectively differentiate pancreatic cancer from other gastrointestinal diseases?
Conclusion
DUPAN-2 is a promising serum marker for pancreatic and bile duct cancer, showing improved specificity compared to other markers.
Supporting Evidence
- DUPAN-2 levels were significantly higher in pancreatic cancer patients compared to those with benign diseases.
- 61% of pancreatic cancer patients tested positive for DUPAN-2 at diagnosis.
- The correlation between DUPAN-2 levels and survival times was statistically significant.
Takeaway
DUPAN-2 is a test that helps doctors find out if someone has pancreatic cancer by checking their blood.
Methodology
The study measured DUPAN-2 levels in serum from patients with various cancers and benign gastrointestinal diseases.
Limitations
The study's findings may not apply to all populations, and the correlation between DUPAN-2 levels and survival was not definitive.
Participant Demographics
Patients included those with pancreatic cancer, gastric cancer, liver metastases, and benign gastrointestinal diseases.
Statistical Information
P-Value
0.041
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website